Table 2

The average tumor burden ±SD of control (PBS) and treated animals and the reduction in tumor burden (%) in the treated animals are reported in the intervention and regression trial. The percent reduction in tumor burden was calculated from the average tumor burden of the treated groups (T) and the average tumor burden of the 13.5-week-old PBS-treated RIP1-Tag2 group by applying the formula (1 – T/C) × 100. Statistical analysis was performed with a two-tailed, unpaired MannWhitney test comparing experimental groups to PBS-injected control mice.P values less than 0.1 are considered statistically significant. Tumor burdens of experimental groups in the regression trial were compared to the tumor burden of 12-week-old Rip1-Tag2 animals. “N start” indicates the number of animals at the beginning of the trial; “N stop” indicates the number of animals at the end of the trial; and “Ntrials” indicates the number of independent experiments.

Treatment groupAverage tumor burden (mm3)N startNstopN trialsP valueReduction in tumor burden (%)
Intervention trial
10-week Rip1-Tag2 starting point4.2  ±   0.5450
13.5-week Rip1-Tag2 PBS control115.4  ±  43.04, 5, 53, 4, 330
AGM-147020.6  ±   7.54, 53, 420.000882.2
BB-9419.6  ±   8.94, 53, 420.000883.0
Fc-endostatin14.1  ±  14.94, 43, 320.001487.8
Fc-angiostatin46.5  ±  21.83, 42, 320.004059.7
Regression trial
12-week Rip1-Tag2 starting point77.3  ±  36.270
13.5-week Rip1-Tag2 control endpoint115.4  ±  43.0100
AGM-1470 (16 weeks)32.3  ±  19.15, 64, 2* 20.035058.8
BB-94 (16 weeks)114.3  ±  53.95410.4121None
Fc-endostatin (16 weeks)106.2  ±  37.55310.3833None
Fc-angiostatin (16 weeks)111.1  ±  47.45310.3833None
Fc-angiostatin + Fc-endostatin (16 weeks)31.8  ±  11.57, 65 20.017758.9
  • * Four mice were left in trial; three mice died at 17.7, 19.5, and 19.8 weeks of age; one mouse is still alive (20.2 weeks at 16 April 1999).

  • Three mice were left in trial and died at 18, 19.5, and 20 weeks of age.